Class effects of SGLT2 inhibitors on cardiorenal outcomes

BACKGROUND: To summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mell...

Descripción completa

Detalles Bibliográficos
Autores principales: Kluger, Aaron Y., Tecson, Kristen M., Lee, Andy Y., Lerma, Edgar V., Rangaswami, Janani, Lepor, Norman E., Cobble, Michael E., McCullough, Peter A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683461/
https://www.ncbi.nlm.nih.gov/pubmed/31382965
http://dx.doi.org/10.1186/s12933-019-0903-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683461/
https://www.ncbi.nlm.nih.gov/pubmed/31382965
http://dx.doi.org/10.1186/s12933-019-0903-4

Ejemplares similares